Abstract: The present invention provides compositions, kits and methods for the selective hybridization and capture of a specific target nucleic acid. The specific target nucleic acid may be present in a heterogeneous mixture of nucleic acids. Selective hybridization and capture provides a target nucleic acid that is substantially free of non-target and/or contaminating nucleic acids. Target nucleic acids that have been selectively hybridized and captured using the current invention are then used in subsequent analysis, wherein the presence of non-target and/or contaminating nucleic acids that interfere with said subsequent analysis have been substantially reduced or eliminated, thereby providing improved analysis results.

Abstract: The present invention provides methods for immobilizing target nucleic acids on a solid support utilizing combinatorial capture probe pairs. These pairs contain first and second capture oligonucleotides that each comprise a target binding region, a capture region and a stem region positioned between the target binding and capture regions. The target binding regions comprise nucleic acid sequences that allow them to hybridize to adjacent regions on the target nucleic acid. The stem regions have nucleic acid sequences that are complementary to each other and the capture regions each comprise a sequence that when positioned adjacent to one another produce a combined nucleic acid sequence that is complementary to a portion of an oligonucleotide bound to a solid support.

Abstract: Provided herein, in some aspects, are methods of imaging molecules without a microscope or other specialized equipment, referred to herein as “microscope-free imaging (MFI).” Herein, “molecular instruments” (e.g., DNA-based and protein-based molecules) are used, instead of microscopes, in a “bottom-up” approach for inspecting molecular targets.

Abstract: Methods and compositions for in situ detection of circular RNA in a tissue sample are provided.

Abstract: The current document is directed to methods and compositions that enable simplified, sensitive, and accurate quantification of nucleic acids. Some methods enable highly parallel measurement of multiple targeted ribonucleic acids from multiple samples. Additional methods enable highly sensitive measurement of low-abundance nucleic acid variants from a complex mixture of nucleic acid molecules.

Abstract: In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of at least one agent that generates a ligatable terminal 5? phosphate group by removing an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, an aprataxin enzyme can catalyze removal of an adenylate group from a terminal 5? phosphate of a nucleic acid. In some embodiments, methods for ligating nucleic acid ends comprise: conducting a nucleic acid ligation reaction in the presence of an aprataxin enzyme under conditions suitable for ligating nucleic acid ends.

Abstract: Methods of coupling adaptors to a target nucleic acid include coupling a first adaptor to a first end of the target nucleic acid to form a coupled first adaptor. A portion of a second adaptor is hybridized to a portion of the coupled first adaptor to form a hybridized second adaptor having a single-stranded 3?-end. The hybridized second adaptor is coupled to a second end of the target nucleic acid to form an adaptor-flanked product having at least a part of the first adaptor coupled to the first end of the target nucleic acid and at least a part of the second adaptor coupled to the second end of the target nucleic acid. These methods can minimize the formation of adaptor-dimers that may be problematic in subsequent complementary nucleic acid strand synthesis, amplification, and sequencing.

Abstract: Methods, devices and systems for analyzing precious samples of cells, including single cells are provided. The methods, devices, and systems in various embodiments of the invention are used to assess genomic heterogeneity, which has been recognized as a central feature of many cancers and plays a critical role in disease initiation, progression, and response to treatment. The methods devices and systems are also used to analyze embryonic biopsies for reimplantation genetic diagnosis (PGD). In one embodiment, the devices, systems and methods provided herein allow for the construction of genomic and RNA-seq libraries without a pre-amplification step.

Abstract: The present invention provides methods and systems for sequencing long nucleic acid fragment. The present invention also provides a method of sequencing a target polynucleotide with fewer probes. Further, the present invention provides a method of sequencing a target polynucleotide with longer reads. Locus-specific, ligation-assisted sequencing/genotyping method and ligation-captured sequencing method are also provided in the present invention. The methods of the present invention allow low-cost, high-throughput and accurate sequencing of nucleic acids.

Abstract: Provided herein are nanostructure-based sequencing methods and systems.

Abstract: The use of markers that participate in inflammatory processes and are associated cytokines in the diagnosis, treatment or prophylaxis of diseases is disclosed. Specifically, cytokines are used to diagnose or treat non-neoplastic or non-leukaemic diseases such as autoimmune diseases or neurodegenerative disorders by the process of taking a DNA bearing sample from a subject animal and analysing the sample to determine the allelic variants present at one or more of the SNP loci at positions ?1082, ?819 and ?592 of the gene encoding IL-10. A method of treating Alzheimer's disease, autoimmune diseases or other neurodegenerative disorders is disclosed by modulating, that is augmenting or decreasing, the function of a gene having one of the allelic polymorphisms of IL-10. IL-6 inhibitors and IL-10 promoters can be used in the manufacture of a medicament for the treatment of prophylaxis of Alzheimer's disease.

Abstract: This invention provides methods for identifying genes associated with cognitive impairment and for identifying compounds useful in the treatment of cognitive impairment. The methods can in particular be used to identify genes associated with, and compounds useful in treating, cognitive impairment in aging.

Abstract: The present invention relates to the use of the editing profile of PDE8A pre-mRNA as a specific bio marker of ADARs activities in evolved primate, particularly in Human tissues. The present invention also relates to an in vitro method for predicting in Human an alteration of the mechanism of the ADARs catalysed pre-mRNA editing of target genes, by analysing the PDE8A pre-mRNA editing profile in a peripheral tissue sample containing cells expressing said PDE8A pre-mRNA, such as blood sample. The present invention is also directed to an in vitro method for the screening of potential therapeutic compound and to predict and assess therapeutic efficacy and/or efficiency or to diagnose potential severe brain or peripheral drug side effects implementing said PDE8A pre-mRNA editing profile as specific biomarker.

Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.

Abstract: The present invention relates to methods of identifying and using risk factors for estimating aneurysm expansion, including high risk expansion in abdominal aortic aneurysm patients, such factors including associated genetic variants and gender differences. In particular, methods of using genetic risk scores and/or patient genotypes are provided for use, including individualizing surveillance for reducing AAA, reducing growth rates of AAA and reducing rates of aneurysm ruptures.

Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

Abstract: Certain embodiments of the invention provide a method of detecting and/or quantitating nonsense mediated RNA decay (NMD) activity in a cell, comprising 1) detecting an altered level of RNA expression of a NMD-sensitive isoform in a cell, as compared to a control cell; and 2) detecting an unaltered level of RNA expression of a corresponding NMD-insensitive isoform in the cell, as compared to a control cell, wherein the isoforms are derived from an endogenously expressed, alternatively spliced gene.

Abstract: The present invention provides a method of assessing whether an individual is at high risk or low risk of inflammatory bowel disease (IBD) progression by determining the expression level of two or more genes in a whole blood sample. Also provided are methods for treating IBD in an individual who is determined to be at high risk or low risk for IBD progression, and kits for assessing whether an individual is at high risk or low risk for IBD progression. Arrays, and methods of providing arrays, of patient-identified selected gene expression products from a whole blood sample of a patient are also provided.

Abstract: The present invention relates to a nucleic acid molecule comprising an annexin A5 (ANXA5) gene regulation element which comprises at least one point mutation, whereby said at least one point mutation (substitution) is selected from the group consisting of (i) a point mutation G to A at a position which corresponds to nucleotide 186 of SEQ ID NO: 2; (ii) a point mutation A to C at a position which corresponds to nucleotide 203 of SEQ ID NO: 2; (iii) a point mutation T to C at a position which corresponds to nucleotide 229 of SEQ ID NO: 2; and (iv) a point mutation G to A at a position which corresponds to nucleotide 276 of SEQ ID NO: 2. Furthermore, the present invention provides for a vector comprising the nucleic acid molecule the invention and a host transformed with the vector. The invention also relates to specific uses, in particular diagnostic uses of the nucleic acid molecules described herein.

Abstract: The present invention is related to an improved method for HER2 gene test by using quantitative real-time PCR (Polymerase Chain Reaction) technique. Our invention streamlines test process, and incorporates quality control for each major step, including sample, reagent, operation, and data report. We eliminate the need for reference genes which is hard to standardize in HER2 PCR test. We develop a cutoff reference point by using the statistical mean of tumor tissue population, and adopt a simplified scoring scheme for evaluation of HER2 status. Our invention produces consistent result across machines and labs, and has proven to be clinically successful in HER2 test.

Abstract: Disclosed herein are methods and kits for identifying a subject as having leukemia. Also provided herein are methods and kits for determining a leukemia subtype in subject. Further provided herein are methods and kits for determining the prognosis of a subject having leukemia and for determining the progression of leukemia in a subject.

Abstract: A method for detecting cancer in an individual comprising detecting a deletion in the nucleic acid sequence between residues 10743 and 12125 in mitochondrial DNA, obtaining a biological sample from the individual, extracting the mitochondrial DNA (mtDNA) from the sample, quantifying the amount of mtDNA in the sample having a deletion in the nucleic acid sequence between residues 10743 and 14125 of the mtDNA genome, and comparing the amount of mtDNA in the sample having the deletion to at least one known reference sample.

Abstract: The present invention relates to the diagnosis of pancreatic cancer, in particular to a salivary mi RNA for use in the diagnosis of pancreatic cancer.

Abstract: The present invention relates to the field of cancer and inflammation, and in particular methods of monitoring, diagnosis, prognosis, detecting, treating and preventing cancer and inflammation conditions. The use of composition comprises method of monitoring, diagnosis, prognosis, and detecting cancer and inflammation with EN2 and/or SATB2 expression and/or activity. The pharmaceutical composition will further comprise agents that inhibit EN2 and/or SATB2 expression or activity.

Abstract: Provided herein are kits, compositions and methods for cancer diagnosis, research and therapy, including but not limited to, cancer markers. In particular, the present invention relates to recurrent gene fusions (e.g., recurrent translocations involving TYK2) as diagnostic markers and clinical targets for cutaneous CD30-positive lymphoproliferative disorders (e.g., lymphomatoid papulosis; primary cutaneous anaplastic large cell lymphoma).

Abstract: Disclosed herein are assays and methods for the identification of premalignant lesions, as well as methods of determining the likelihood that such premalignant lesions will progress to lung cancer. Also disclosed are methods and assays that are useful for monitoring the progression of premalignant lesions to lung cancer. The assays and methods disclosed herein provide minimally invasive means of accurately detecting and monitoring the presence or absence of premalignant lesions, thus providing novel insights into the earliest stages of lung cancer and facilitating early detection and early intervention.

Abstract: This invention relates methods and compositions for identifying Colorectal Cancer (CRC) prognostic transcripts and groups of CRC prognostic transcripts useful in determining the prognosis of cancer in a patient, particularly for gastrointestinal cancer, such as gastric or colorectal cancer. Specifically, this invention relates to CRC cell culture-based methods to identify cell proliferation signatures.

Abstract: This invention is related to novel PNA probes, probe sets, methods and kits pertaining to the detection of one or more species of Candida yeast. Non-limiting examples of probing nucleobase sequences that can be used for the probes of this invention can be selected from the group consisting of: AGA-GAG-CAG-CAT-GCA (Seq. Id. No. 1), AGA-GAG-CAA-CAT-GCA (Seq. Id. No. 2), ACA-GCA-GAA-GCC-GTG (Seq. Id. No. 3), CAT-AAA-TGG-CTA-CCA-GA (Seq. Id. No. 4), CAT-AAA-TGG-CTA-CCC-AG (Seq. Id. No. 5), ACT-TGG-AGT-CGA-TAG (Seq. Id. No. 6), CCA-AGG-CTT-ATA-CTC-GC (Seq. Id. No. 7), CCC-CTG-AAT-CGG-GAT (Seq. Id. No. 8), GAC-GCC-AAA-GAC-GCC (Seq. Id. No. 9), ATC-GTC-AGA-GGC-TAT-AA (Seq. Id. No. 10), TAG-CCA-GAA-GAA-AGG (Seq. Id. No. 11), CAT-AAA-TGG-CTA-GCC-AG (Seq. Id. No. 12), CTC-CGA-TGT-GAC-TGC-G (Seq. Id. No. 13), TCC-CAG-ACT-GCT-CGG (Seq. Id. No. 14), TCC-AAG-AGG-TCG-AGA (Seq. Id. No. 15), GCC-AAG-CCA-CAA-GGA (Seq. Id. No. 16), GCC-GCC-AAG-CCA-CA (Seq. Id. No. 17), GGA-CTT-GGG-GTT-AG (Seq. Id. No.

Abstract: The present disclosure provides a system and methods for detecting and identifying plant events that contain donor sequences inserted precisely into a targeted genomic loci, and plants and plant cells comprising such targeted genomic loci. The method comprises the steps of amplifying a genomic DNA with a first round of PCR to produce an amplicon from donor sequences inserted in the reverse orientation, wherein the production of the amplicon indicates the presence of the site specific integration event.

Abstract: A method for obtaining self-cleaning and self-sanitizing surfaces of finished leather, comprising the steps of deposition of two coating layers containing respective active mixtures on the finished leather surface, in which a first active mixture comprises a film-forming compound based on polymers and filler, a flow additive compound, a cross-linking compound, an anti-oxidant compound and an aqueous dispersion, and a second active mixture comprises a water-based auxiliary flow additive compound, a silicone emulsion, a solvent aliphatic prepolymer, a photo-catalyst compound, a water repellent agent, a biocide action powder agent and solvent agents and/or wetting agents and/or dispersing agents and/or anti-foam agents.

Abstract: Provided is a method for manufacturing reduced iron which includes the steps of: i) drying ores in an ore drier; ii) supplying the dried ores to at least one reduction reactor; iii) reducing the ores in the at least one reduction reactor and manufacturing reduced iron; iv) discharging exhaust gas by which the ores are reduced in the reduction reactor; v) branching the exhaust gas and providing the branched exhaust gas as ore feeding gas; and vi) exchanging heat between the exhaust gas and the ore feeding gas and transferring the sensible heat of the exhaust gas to the ore feeding gas. In the supplying the dried ores to the at least one reduction reactor, the dried ores are supplied to the at least one reduction reactor by using the ore feeding gas.

Abstract: A vapor film-rupturing agent is provided that is prepared from asphalt as a staring material, so as to have a fraction (x) (% by mass) of a saturated component and a fraction (y) (% by mass) of an asphaltene component based on the total fraction 100% by mass of the saturated component, the asphaltene component, an aromatic component, and a resin component obtained by any one of analysis methods described in the Japan Petroleum Institute Standard and Manuals Testing Method for Petroleum Products JPI-5S-70-10 and the British Standard Test Method IP-469 that satisfy one or more of the following conditions (1) to (3): condition (1): 1.2926×(x)/100?8.113×(y)/100+2.3384?2.400, condition (2): (y) ?7.0, and condition (3): ((y)/(x)) ?0.5. The vapor film-rupturing agent is capable of preparing a thermal treatment oil composition having a high vapor film-rupturing effect with a characteristic number of seconds in the cooling capability test according to JIS K2242 (2012) of 2.50 seconds or less.

Abstract: This disclosure is related to high yield strength steel where yield strength can be increased without significantly affecting ultimate tensile strength (UTS) and in some cases, higher yield strength can be obtained without significant decrease in ultimate tensile strength and total elongation.

Abstract: A method of evaluating a residual stress including a condition setting step of setting a processing condition of water jet peening for a processing target; an analysis step of analyzing a jet flow when a fluid is injected from a nozzle model to a processing target model in accordance with the processing condition, and obtaining a void fraction which is a volume fraction of babbles contained in a unit volume of the fluid, and a collapse fraction, which is a volume fraction of the bubbles which collapse in a unit time in the unit volume of the fluid, at each position on a surface of the processing target model; an impact pressure correlation value calculating step of obtaining an impact pressure correlation value, which is a product of the void fraction and the collapse fraction at each position; an experimental value acquisition step of obtaining an impact pressure experimental value.

Abstract: Provided is an oriented electrical steel sheet including a groove existing on the surface of the electrical steel sheet and a forsterite layer formed on a part or all of the surface of the electrical steel sheet, in which forsterite which is extended from the forsterite layer and penetrates to a base steel sheet in an anchor form is present on the surface of the side of the groove.

Abstract: Disclosed herein is a high-strength plated steel sheet containing an internal oxidized layer, a soft layer including the internal oxidized layer, and a hard layer including a structure having metallic structure containing a low-temperature-transformation produced phase in a proportion of 70% or more by area of the whole of the metallic structure, in which polygonal ferrite is in a proportion of 0% or more by area, and 10% or less by area of the same, and retained austenite is in a proportion of 5% or more by volume of the same. The high-strength plated steel sheet satisfies the average depth D of the soft layer is 20 ?m or more, the average depth d of the internal oxidized layer is 4 ?m or more and less than D, and a tensile strength of 980 MPa or more.

Abstract: The present invention relates to a method of separating radioactive elements from a mixture, wherein the mixture is treated with at least one alkanesulfonic acid and at least one further acid, selected from the group consisting of hydrochloric acid, nitric acid, amidosulfonic acid and mixtures thereof and also the use of at least one alkanesulfonic acid and at least one further acid for separating radioactive elements from mixtures comprising these.

Abstract: A method of producing a composite material comprising: supplying a metal compound (MPC) of a product metal (MP) and a reductant (R) capable of reducing the metal compound (MPC) of the product metal (MP) to a reactor; forming a composite material comprising a matrix of oxidised reductant (R0) of the reductant (R), the product metal (MP) dispersed in the matrix of oxidised reductant (R0), and at least one of (i) one or more metal compounds (MPCR) of the metal compound (MPC) in one or more oxidation states and (ii) the reductant (R); and recovering the composite material from the reactor, wherein the metal compound (MPC) of the product metal (MP) is fed to the reactor such that it is in excess relative to the reductant (R).

Abstract: A method comprises sorting and removing impurities from magnesium alloy waste material, and cleaning and drying said material, the cleaning being high-pressure rinsing, pickling, and water washing, performed in sequence. The method employs high-pressure rinsing during the pretreatment of magnesium alloy waste material; the cleaning effectiveness is excellent, the effectiveness of the removal of impurities from the surface of the magnesium alloy waste material is much better than in conventional processes, and the amount of clean waste material can exceed 90% of the total amount of processed waste material; the clean magnesium alloy waste material obtained from the pretreatment method may be used as the entire raw materials for casting national-standard alloy ingots, the addition of costly high-purity magnesium is unnecessary, and the amount of alloy raw material that must be added is significantly reduced; during processing, little waste material is lost, costs are low, and efficiency is high.

Abstract: Provided are: an extractant which is capable of quickly and highly efficiently extracting zirconium from an acidic solution that is obtained by acid leaching a material containing zirconium and scandium such as an SOFC electrode material; and a method for extracting zirconium, which uses this extractant. A zirconium extractant according to the present invention is composed of an amide derivative represented by general formula (I). In the formula, R1 and R2 respectively represent the same or different alkyl groups, each of which may be linear or branched; R3 represents a hydrogen atom or an alkyl group; and R4 represents a hydrogen atom or an arbitrary group other than an amino group, said arbitrary group being bonded, as an amino acid, to the ? carbon.

Abstract: A copper-zinc alloy contains 59.0 to 65.0% Cu, 2.5 to 4.0% Mn, 1.2 to 2.5% Al, 0.5 to 2.0% Si, 0.2 to 1.0% Fe, 0 to 1.0% Pb, 0 to 1.5% Ni, 0 to 0.2% Sn, balance Zn and unavoidable impurities. The zinc alloy has excellent temperature resistance and surfaces produced by machining have a considerably reduced surface roughness.

Abstract: A process to increase ductility includes utilizing ?-TiAl alloy as a base alloy and reducing at least one interstitial of the base alloy to create an alloy compositions with extremely low interstitials (Eli).

Abstract: Aluminum alloys having improved properties are provided. The alloy includes about 8 to about 12 weight percent silicon, about 0.5 to about 1.5 weight percent copper, about 0.2 to about 0.4 weight percent magnesium, 0 to about 0.5 weight percent iron, about 0.3 to about 0.6 weight percent manganese, 0 to about 1.5 weight percent nickel, and 0 to about 0.5 weight percent zinc. Aluminum may be present in an amount between about 80 and 91 weight percent. The alloy may include about 0.1 to about 0.5 weight percent each of trace elements such as titanium, vanadium, and/or zirconium, and up to about 0.25 weight percent of all other trace elements. In addition, the alloy may contain about 0.03 to about 0.1 weight percent of strontium, sodium, and/or antimony, and up to 5 ppm phosphorus. Also disclosed is a high pressure die cast article, such as an engine block.

Abstract: 5000 series aluminum wrought alloys with high strength, high formability, excellent corrosion resistance, and friction-stir weldability, and methods of making those alloys.

Abstract: Aluminum alloys, fabricated by a rapid solidification process, with high strength, high ductility, high corrosion resistance, high creep resistance, and good weldability.

Abstract: A corrodible downhole article includes a magnesium alloy. The magnesium alloy includes: 1-9 wt % Zn; 1-2 wt % Cu; 0.5-1.0 wt % Mn; and 0.1-5 wt % of a corrosion promoting element (e.g., Ni). The alloy can have a 0.2% proof strength of at least 150 MPa when tested using standard tensile test method ASTM B557-10.

Abstract: According to one implementation, a magnesium-lithium alloy contains not less than 10.50 mass % and not more than 16.00 mass % lithium, not less than 5.00 mass % and not more than 12.00 mass % aluminum, and not less than 2.00 mass % and not more than 8.00 mass % calcium. According to one implementation, a rolled stock is made of the above-mentioned magnesium-lithium alloy. According to one implementation, a processed product includes the above-mentioned magnesium-lithium alloy as a material.

Abstract: The invention relates to a cemented carbide composition producing method for precious metal, which includes a titanium nitride component contained therein and shows excellent workability, corrosion resistance, reduction in weight and other desirable mechanical properties, as well as the low amount of nickel used as a metallic binder and an aluminum oxide coating helps to suppress potential negative skin reactions.

Abstract: The invention relates to a hot-rolled steel sheet having a tensile strength of greater than 1200 MPa, an Re/Rm ratio of less than 0.75 and an elongation at break of greater than 10%, the composition of which contains, the contents being expressed by weight: 0.10%?C?0.25%; 1%?Mn?3%; Al?0.015%; Si?1.985%; Mo?0.30%; Cr?1.5%; S?0.015%; P?0.1%; Co?1.5%; B?0.005%; it being understood that 1%?Si+Al?2%; Cr +(3×Mo)?0.3%, the balance of the composition consisting of iron and inevitable impurities resulting from the smelting, the microstructure of the steel consisting of at least 75% bainite, residual austenite in an amount equal to or greater than 5% and martensite in an amount equal to or greater than 2%.

Abstract: A method of manufacturing a part including selective laser melting of a powder including a steel alloy containing, by weight, 16% to 19% chromium and 12.2% to 13.5% nickel, wherein the powder is substantially non-magnetic.